Pharming Group N.V. (PHAR)

Pharming Group Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	12.85	-8.49	-12.01	14.99	23.08
Depreciation & Amortization	11.22	16.07	15.93	13.19	19.61
Stock-Based Compensation	13.77	11.25	9.25	6.39	9.06
Other Adjustments	9.02	-0.17	-15.73	-10.57	-8.99
Change in Receivables	-3.36	-6.78	-18.54	2.36	5.92
Changes in Inventories	-1.29	-0.5	-14.43	-15.02	-6.15
Changes in Accounts Payable	14.13	-2.77	16.23	11.99	-5.19
Changes in Income Taxes Payable	-4.6	-15.58	-0.66	-1.24	-
Changes in Other Operating Activities	2.97	5.18	2.67	0.36	0.52
Operating Cash Flow	54.71	-1.8	-17.3	22.46	37.84
Operating Cash Flow Growth	-	-	-	-40.65%	-54.75%
Capital Expenditures	-0.75	-0.79	-1.44	-1.38	-10.74
Purchases of Intangible Assets	-0.01	-0.01	-0.03	-0.6	-5.98
Proceeds from Sale of Intangible Assets	-	-	21.28	-	-
Purchases of Investments	-0.74	-284.31	-382.01	-	-4.59
Proceeds from Sale of Investments	85.23	316.73	232.81	7.3	-
Payments for Business Acquisitions	-57.48	-	-	-	-
Investing Cash Flow	26.25	31.62	-129.39	5.32	-21.31
Long-Term Debt Issued	-	104.54	-	-	-
Long-Term Debt Repaid	-4.25	-138.93	-4.04	-3.31	-3.22
Net Long-Term Debt Issued (Repaid)	-4.25	-34.39	-4.04	-3.31	-3.22
Other Financing Activities	5.74	-0.02	3	-1.67	-24.73
Financing Cash Flow	1.5	-34.41	-1.04	-4.98	-27.95
Effect of Exchange Rate Changes on Cash and Cash Equivalents	7.91	-2.21	2.13	-7.38	-1.83
Net Cash Flow	82.45	-4.59	-147.73	22.8	-11.41
Free Cash Flow	53.96	-2.59	-18.74	21.08	27.1
Free Cash Flow Growth	-	-	-	-22.21%	-65.68%
FCF Margin	14.35%	-0.87%	-7.64%	10.25%	13.63%
Free Cash Flow Per Share	0.72	-0.03	-0.26	0.30	0.39
Levered Free Cash Flow	20.28	-44.63	3.71	18.27	10.82
Unlevered Free Cash Flow	40.99	-9.19	-10.44	27.74	11.61

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q